|Bid||9.98 x 1400|
|Ask||10.02 x 800|
|Day's Range||9.99 - 10.00|
|52 Week Range||9.66 - 10.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A St. Petersburg-based special purpose acquisition company is terminating a merger agreement two months after inking the deal. Isleworth Healthcare Acquisition Corp. (Nasdaq: ISLE) and Aventura-based Cytovia Holdings Inc. agreed to the mutual termination agreement on June 30 after both companies’ boards of directors determined the merger would not be in stockholders’ best interests, according to documents filed with the U.S. Securities and Exchange Commission. SPAC mergers have been upended by market turmoil, with at least four deals falling through within a 24-hour period at the start of the month as the S&P 500 slipped into bear market territory for the first time since March 2020, according to Bloomberg SPAC Research.
About 14 months after inking a natural killer cell deal with Cellectis SA (NASDAQ: CLLS), Cytovia plans to list on NASDAQ via a merger with the SPAC Isleworth Healthcare Acquisition Corp (NASDAQ: ISLE). The company went on to create a China joint venture. The biotech teamed up with China-based biotech investor TF Capital to form CytoLynx Therapeutics with $45 million in funding in September 2021. Related: Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China. The blank-
A look at the shareholders of Isleworth Healthcare Acquisition Corp. ( NASDAQ:ISLE ) can tell us which group is most...